{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T22:26:23Z","timestamp":1781130383240,"version":"3.54.1"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tirbanibulin is an approved topical treatment for actinic keratosis (AK). This non\u2010interventional study investigated effectiveness and safety of tirbanibulin for AK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>The prospective KLIR\u2010study was conducted at 58 German dermatology centers (02\/2022\u201309\/2023). Patients received tirbanibulin once daily for 5 consecutive days. Lesion count reduction, clearance rates, safety, and treatment satisfaction were assessed at day 57 (visit\u00a03) after treatment. Visits on days 0, 8\u201329, and 240 allowed for the evaluation of baseline data, local skin reaction (LSR) peaks, and lesion recurrence, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 545 AK patients were included in the study. The mean number of AK lesions decreased from 5.9 (baseline) to 1.9 at visit\u00a03, representing a 70% lesion count reduction (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.0001). Clearance rates at visit\u00a03 were 37.4% (complete clearance) and 55.0% (partial clearance \u2265\u00a075% reduction). Among patients with complete clearance at visit\u00a03, 21.9% experienced recurrent AK lesions at visit\u00a04. The majority of LSRs were mild or moderate. Erythema (97.6%) was the most common LSR. Overall, 91.5% of patients rated their AK lesions as improved and 99% would consider future tirbanibulin treatment (\u201cdefinitely\u201d, \u201ccertainly\u201d, \u201cprobably\u201d, \u201cmaybe\u201d).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tirbanibulin showed high lesion clearance and a high level of acceptance in real\u2010life conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ddg.15876","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:59:52Z","timestamp":1758794392000},"page":"186-193","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real\u2010world evidence of tirbanibulin in the treatment of actinic keratosis in Germany \u2013 prospective, multicenter, non\u2010interventional KLIR study"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-1825","authenticated-orcid":false,"given":"Markus V.","family":"Heppt","sequence":"first","affiliation":[{"name":"Department of Dermatology University Hospital Erlangen Friedrich\u2010Alexander University Erlangen\u2010N\u00fcrnberg  Erlangen Germany"},{"name":"Comprehensive Cancer Center Erlangen\u2010EMN  Erlangen Germany"},{"name":"Bavarian Cancer Research Center (BZKF)  Erlangen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Hadshiew","sequence":"additional","affiliation":[{"name":"MVZ Derma Cologne  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afra","family":"Kempf","sequence":"additional","affiliation":[{"name":"Almirall Hermal  Reinbek Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Melzer","sequence":"additional","affiliation":[{"name":"Almirall Hermal  Reinbek Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0229-8931","authenticated-orcid":false,"given":"Carola","family":"Berking","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Erlangen Friedrich\u2010Alexander University Erlangen\u2010N\u00fcrnberg  Erlangen Germany"},{"name":"Comprehensive Cancer Center Erlangen\u2010EMN  Erlangen Germany"},{"name":"Bavarian Cancer Research Center (BZKF)  Erlangen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"e_1_2_7_2_1","volume-title":"Actinic Keratosis","author":"Marques E","year":"2023"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14753"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024040"},{"key":"e_1_2_7_5_1","first-page":"462","article-title":"New histopathological classification of actinic keratosis (incipient intraepidermal squamous cell carcinoma)","volume":"4","author":"Cockerell CJ","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1085-5629(99)80003-0"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14151"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14048"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12848"},{"key":"e_1_2_7_10_1","first-page":"1249","article-title":"[S3\u2010Leitlinie \"Aktinische Keratose und Plattenepithelkarzinom der Haut\" \u2013 Update 2023, Teil 1: Therapie der aktinischen Keratose, Morbus Bowen, Cheilitis actinica, berufsbedingte Erkrankung und Versorgungsstrukturen: S3 guideline \u201cactinic keratosis and cutaneous squamous cell carcinoma\u201d","volume":"21","author":"Heppt MV","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19897"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630310012118"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01479-0"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19636"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.2020.5576"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2024.07.001"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1368"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60020225"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12144837"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17168"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.8264"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630701818870"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211031329"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1024"},{"key":"e_1_2_7_25_1","unstructured":"A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp (AKtive) ClinicalTrials.gov. Avalaible from:https:\/\/clinicaltrials.gov\/study\/NCT05387525?intr=Tirbanibulin&rank=10&page=1&limit=10(2025) (Last accessed April 8 2025)."},{"key":"e_1_2_7_26_1","unstructured":"A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis (TirbAKare) ClinicalTrial.giv. Avalaible from:https:\/\/clinicaltrials.gov\/study\/NCT06135415?intr=Tirbanibulin&rank=6&page=1&limit=10(2025) (Last accessed April 8 2025)."}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.15876","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ddg.15876","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.15876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:29:44Z","timestamp":1781087384000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.15876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/ddg.15876"],"URL":"https:\/\/doi.org\/10.1111\/ddg.15876","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"2025-02-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}